Primary liver cancer
Conditions
Interventions
Experimental group:EGCG+TACE
Sponsors
The People's Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Obtain informed consent signed by the patient prior to the commencement of any study related procedures. Patients have fully understood the study and voluntarily signed written informed consent; 2.The proportion of tumor in the whole liver was less than 70% in patients with unresectable middle and advanced primary liver cancer; 3.According to RECIST (Version 1.1), there is at least one measurable lesion that has not been locally treated; 4.Child-Pugh Score less than 10; 5.The functions of all organs were basically normal (laboratory test results within 1 week before enrollment without continuous support therapy): white blood cells >3.0x10^9/L, platelets >70x10^9/L, hemoglobin >9.0g/ dL; Serum creatinine 3 months; 8.The compliance of patients participating in this clinical study was good.
Exclusion criteria
Exclusion criteria: 1.Blood coagulation function has Serious declined,and unable to correct. 2.Portal venous trunk was completely stuffed with tumor emboli, and less collateral circulation formation; 3.Extrahepatic metastasis of tumor; 4.Patients scheduled for liver transplantation; 5.Pregnancy or lactation women; 6.Patients with severe and uncontrolled organic diseases or infections, such as decompensated heart, lung, and renal failure, that cannot tolerate chemotherapy; 7.Patients with previous severe psychological or psychiatric disorders, drug addiction or alcohol dependence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress Free Survival (PFS);Overall Survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life;Liver injury;Tumour size;Objective Response Rate (ORR); | — |
Countries
China
Contacts
Public ContactZhang Guo
The People's Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed